Sandostatin LAR Depot — CareFirst (Caremark)

Initial criteria

• Treatment of pheochromocytoma or paraganglioma

Reauthorization criteria

• Member is experiencing clinical benefit as evidenced by improvement or stabilization in clinical signs and symptoms since initiation of therapy

Approval duration

12 months